Israel Englander Inmune Bio, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 241,248 shares of INMB stock, worth $583,820. This represents 0.0% of its overall portfolio holdings.

Number of Shares

241,248

Previous 291,327 17.19%

Holding current value

$583,820

Previous $1.36 Million 38.53%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.93 - $10.48 $246,889 - $524,827	-50,079 Reduced 17.19%	241,248 $1.88 Million
Q4 2024 Feb 14, 2025	BUY	$4.4 - $6.43 $390,821 - $571,131	88,823 Added 43.86%	291,327 $1.36 Million
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $533,793 - $1.08 Million	109,834 Added 118.52%	202,504 $1.09 Million
Q2 2024 Aug 14, 2024	SELL	$7.15 - $11.84 $475,632 - $787,620	-66,522 Reduced 41.79%	92,670 $817,000
Q1 2024 May 15, 2024	BUY	$10.53 - $14.01 $1.42 Million - $1.89 Million	134,988 Added 557.71%	159,192 $1.87 Million
Q4 2023 Feb 14, 2024	SELL	$6.6 - $11.52 $26,017 - $45,411	-3,942 Reduced 14.01%	24,204 $272,000
Q2 2023 Aug 14, 2023	BUY	$6.5 - $10.09 $68,412 - $106,197	10,525 Added 59.73%	28,146 $255,000
Q1 2023 May 15, 2023	BUY	$6.01 - $10.18 $5,943 - $10,068	989 Added 5.95%	17,621 $114,000
Q4 2022 Feb 14, 2023	SELL	$6.13 - $7.96 $64,591 - $83,874	-10,537 Reduced 38.78%	16,632 $105,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $10.44 $164,100 - $283,644	27,169 New	27,169 $168,000

Others Institutions Holding INMB

# of Institutions

Shares Held

6.98M

Call Options Held

317K

Put Options Held

1.81M

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $43.4M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account